Exploring the mechanisms of action of probiotics in depression: Results from a randomized controlled pilot trial

Viktoriya Nikolova; Anthony Cleare; Allan Young; James Stone

doi:10.1016/j.jad.2025.01.153

Exploring the mechanisms of action of probiotics in depression: Results from a randomized controlled pilot trial

Viktoriya Nikolova, Anthony Cleare, Allan Young, James Stone

University of Sussex

Research output: Contribution to journal › Article › peer-review

Abstract

Background: We previously reported greater reductions in depression and anxiety following probiotic supplementation in people with major depressive disorder (MDD) in a randomised double-blind placebo-controlled pilot trial (Nikolova et al., 2023). Here, we investigate the mechanisms underlying these effects. Methods: 49 people with MDD received a multi-strain probiotic (n = 24) or placebo (n = 25) for 8 weeks in addition to their antidepressant. Stool and blood samples were collected to analyse gut microbiota composition and inflammatory cytokines. Stool samples from 25 matched healthy volunteers (HVs) were also obtained. Results: Within the probiotic group, there was a significant increase in richness according to Chao1(bias-corrected) (w4 p = 0.04) and a trend for increased Total count (w4 p = 0.06, w8 p = 0.09) compared to baseline, but not to placebo. When compared to HVs post-treatment, only the placebo group had a significant decrease in Shannon’ entropy (p = 0.03) and a trend for decreased Total count (p = 0.08) and Simpson's index (p = 0.09). Between-group differences in beta diversity were observed at week 4 (p = 0.04), but not week 8. Consistent between-group differences were seen in family Bacilleceae post-treatment (FDR p < 0.05), which correlated with decreases in anxiety (FDR p < 0.05). There were no differences in inflammatory markers. Limitations: This study was limited by data loss during the COVID-19 Pandemic. Conclusion: Probiotics may positively impact the microbiota by normalising diversity and increasing levels of health-related taxa, which may partially account for their benefits in MDD. Understanding how these changes relate to symptom improvement can inform their targeted use in clinical practice. Larger trials incorporating functional multi-omics are needed.

Original language	English
Pages (from-to)	241-250
Number of pages	10
Journal	Journal of Affective Disorders
Volume	376
Early online date	10 Feb 2025
DOIs	https://doi.org/10.1016/j.jad.2025.01.153
Publication status	E-pub ahead of print - 10 Feb 2025

Access to Document

10.1016/j.jad.2025.01.153Licence: CC BY

Cite this

@article{0df81c747607415aad98dae815ca6784,

title = "Exploring the mechanisms of action of probiotics in depression: Results from a randomized controlled pilot trial",

abstract = "Background: We previously reported greater reductions in depression and anxiety following probiotic supplementation in people with major depressive disorder (MDD) in a randomised double-blind placebo-controlled pilot trial (Nikolova et al., 2023). Here, we investigate the mechanisms underlying these effects. Methods: 49 people with MDD received a multi-strain probiotic (n = 24) or placebo (n = 25) for 8 weeks in addition to their antidepressant. Stool and blood samples were collected to analyse gut microbiota composition and inflammatory cytokines. Stool samples from 25 matched healthy volunteers (HVs) were also obtained. Results: Within the probiotic group, there was a significant increase in richness according to Chao1(bias-corrected) (w4 p = 0.04) and a trend for increased Total count (w4 p = 0.06, w8 p = 0.09) compared to baseline, but not to placebo. When compared to HVs post-treatment, only the placebo group had a significant decrease in Shannon{\textquoteright} entropy (p = 0.03) and a trend for decreased Total count (p = 0.08) and Simpson's index (p = 0.09). Between-group differences in beta diversity were observed at week 4 (p = 0.04), but not week 8. Consistent between-group differences were seen in family Bacilleceae post-treatment (FDR p < 0.05), which correlated with decreases in anxiety (FDR p < 0.05). There were no differences in inflammatory markers. Limitations: This study was limited by data loss during the COVID-19 Pandemic. Conclusion: Probiotics may positively impact the microbiota by normalising diversity and increasing levels of health-related taxa, which may partially account for their benefits in MDD. Understanding how these changes relate to symptom improvement can inform their targeted use in clinical practice. Larger trials incorporating functional multi-omics are needed.",

author = "Viktoriya Nikolova and Anthony Cleare and Allan Young and James Stone",

note = "Publisher Copyright: {\textcopyright} 2025 The Authors",

year = "2025",

month = feb,

day = "10",

doi = "10.1016/j.jad.2025.01.153",

language = "English",

volume = "376",

pages = "241--250",

journal = "Journal of Affective Disorders",

issn = "0165-0327",

publisher = "Elsevier",

}

TY - JOUR

T1 - Exploring the mechanisms of action of probiotics in depression

T2 - Results from a randomized controlled pilot trial

AU - Nikolova, Viktoriya

AU - Cleare, Anthony

AU - Young, Allan

AU - Stone, James

PY - 2025/2/10

Y1 - 2025/2/10

N2 - Background: We previously reported greater reductions in depression and anxiety following probiotic supplementation in people with major depressive disorder (MDD) in a randomised double-blind placebo-controlled pilot trial (Nikolova et al., 2023). Here, we investigate the mechanisms underlying these effects. Methods: 49 people with MDD received a multi-strain probiotic (n = 24) or placebo (n = 25) for 8 weeks in addition to their antidepressant. Stool and blood samples were collected to analyse gut microbiota composition and inflammatory cytokines. Stool samples from 25 matched healthy volunteers (HVs) were also obtained. Results: Within the probiotic group, there was a significant increase in richness according to Chao1(bias-corrected) (w4 p = 0.04) and a trend for increased Total count (w4 p = 0.06, w8 p = 0.09) compared to baseline, but not to placebo. When compared to HVs post-treatment, only the placebo group had a significant decrease in Shannon’ entropy (p = 0.03) and a trend for decreased Total count (p = 0.08) and Simpson's index (p = 0.09). Between-group differences in beta diversity were observed at week 4 (p = 0.04), but not week 8. Consistent between-group differences were seen in family Bacilleceae post-treatment (FDR p < 0.05), which correlated with decreases in anxiety (FDR p < 0.05). There were no differences in inflammatory markers. Limitations: This study was limited by data loss during the COVID-19 Pandemic. Conclusion: Probiotics may positively impact the microbiota by normalising diversity and increasing levels of health-related taxa, which may partially account for their benefits in MDD. Understanding how these changes relate to symptom improvement can inform their targeted use in clinical practice. Larger trials incorporating functional multi-omics are needed.

AB - Background: We previously reported greater reductions in depression and anxiety following probiotic supplementation in people with major depressive disorder (MDD) in a randomised double-blind placebo-controlled pilot trial (Nikolova et al., 2023). Here, we investigate the mechanisms underlying these effects. Methods: 49 people with MDD received a multi-strain probiotic (n = 24) or placebo (n = 25) for 8 weeks in addition to their antidepressant. Stool and blood samples were collected to analyse gut microbiota composition and inflammatory cytokines. Stool samples from 25 matched healthy volunteers (HVs) were also obtained. Results: Within the probiotic group, there was a significant increase in richness according to Chao1(bias-corrected) (w4 p = 0.04) and a trend for increased Total count (w4 p = 0.06, w8 p = 0.09) compared to baseline, but not to placebo. When compared to HVs post-treatment, only the placebo group had a significant decrease in Shannon’ entropy (p = 0.03) and a trend for decreased Total count (p = 0.08) and Simpson's index (p = 0.09). Between-group differences in beta diversity were observed at week 4 (p = 0.04), but not week 8. Consistent between-group differences were seen in family Bacilleceae post-treatment (FDR p < 0.05), which correlated with decreases in anxiety (FDR p < 0.05). There were no differences in inflammatory markers. Limitations: This study was limited by data loss during the COVID-19 Pandemic. Conclusion: Probiotics may positively impact the microbiota by normalising diversity and increasing levels of health-related taxa, which may partially account for their benefits in MDD. Understanding how these changes relate to symptom improvement can inform their targeted use in clinical practice. Larger trials incorporating functional multi-omics are needed.

UR - http://www.scopus.com/inward/record.url?scp=85217139687&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2025.01.153

DO - 10.1016/j.jad.2025.01.153

M3 - Article

SN - 0165-0327

VL - 376

SP - 241

EP - 250

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

ER -

Exploring the mechanisms of action of probiotics in depression: Results from a randomized controlled pilot trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this